Meeting
2019 Genitourinary Cancers Symposium
Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
Authors
Brian I. Rini
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Brian I. Rini , Leonard Joseph Appleman , Robert A. Figlin , Elizabeth R. Plimack , Jaime R. Merchan , Keshi Wang , Sanjay Thamake , Naseem J. Zojwalla , Toni K. Choueiri , David F. McDermott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02293980
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 558)
DOI
10.1200/JCO.2019.37.7_suppl.558
Abstract #
558
Poster Bd #
D19
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.
First Author: Catherine S. Magid Diefenbach
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.
First Author: Christos Kyriakopoulos
Poster
2023 ASCO Annual Meeting
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
First Author: Joseph J. Sacco
Poster
2023 ASCO Annual Meeting
ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors.
First Author: Toni K. Choueiri